Catalyst Funds Management Pty Ltd Grows Holdings in Enhabit, Inc. (NYSE:EHAB)

Catalyst Funds Management Pty Ltd lifted its position in shares of Enhabit, Inc. (NYSE:EHAB) by 34.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,100 shares of the company’s stock after acquiring an additional 9,700 shares during the quarter. Catalyst Funds Management Pty Ltd owned 0.08% of Enhabit worth $298,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. FMR LLC boosted its position in Enhabit by 138.4% during the third quarter. FMR LLC now owns 3,388 shares of the company’s stock worth $27,000 after purchasing an additional 1,967 shares in the last quarter. Gladius Capital Management LP raised its stake in shares of Enhabit by 78.2% during the 3rd quarter. Gladius Capital Management LP now owns 6,259 shares of the company’s stock worth $49,000 after buying an additional 2,747 shares during the period. Intech Investment Management LLC purchased a new position in shares of Enhabit during the 3rd quarter valued at approximately $96,000. Versor Investments LP acquired a new stake in Enhabit in the 3rd quarter valued at $97,000. Finally, Stoneridge Investment Partners LLC increased its holdings in Enhabit by 22.6% in the 4th quarter. Stoneridge Investment Partners LLC now owns 12,533 shares of the company’s stock worth $98,000 after acquiring an additional 2,308 shares in the last quarter.

Enhabit Trading Up 0.8 %

Shares of EHAB stock opened at $8.58 on Friday. Enhabit, Inc. has a fifty-two week low of $6.85 and a fifty-two week high of $11.74. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.46 and a current ratio of 1.46. The stock’s fifty day moving average is $8.28 and its two-hundred day moving average is $7.92. The firm has a market capitalization of $432.87 million, a P/E ratio of -3.70 and a beta of 1.80.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Leerink Partners reaffirmed a “market perform” rating and set a $8.00 price objective (down from $8.50) on shares of Enhabit in a report on Tuesday, November 19th. Jefferies Financial Group reiterated a “buy” rating on shares of Enhabit in a report on Thursday, March 6th.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.